Paper · 42903418
Molecular mechanisms and therapeutic strategies of immunotherapy resistance in esophageal cancer.
Pang Y and 8 others. Front Immunol, 2026.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Molecular mechanisms and therapeutic strategies of immunotherapy resistance in esophageal cancer. Papers, record 42903418. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42903418
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Molecular mechanisms and therapeutic strategies of immunotherapy resistance in esophageal cancer.
- Journal
- Front Immunol
- Year
- 2026
- Publication types
- Journal Article, Review, Research Support, Non-U.S. Gov't
- Revised in PubMed
- 2026-10-30
Source PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Esophageal Neoplasms | Major topic |
| Drug Resistance, Neoplasm | Major topic |
| Immunotherapy | Major topic |
| Immune Checkpoint Inhibitors | Major topic |
| Humans | |
| Tumor Microenvironment | |
| Metabolic Reprogramming | |
| Animals | |
| Epigenesis, Genetic |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References158
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 40,640,393 | A bispecific antibody-drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial. | Nat Med | 2025 | https://conductscience.org/library/papers/40640393 | PubMed |
| 2 | 40,179,324 | NOTCH1 Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial. | J Clin Oncol | 2025 | https://conductscience.org/library/papers/40179324 | PubMed |
| 3 | 33,546,704 | The cancer metabolic reprogramming and immune response. | Mol Cancer | 2021 | https://conductscience.org/library/papers/33546704 | PubMed |
| 4 | 37,723,150 | Intracellular Fusobacterium nucleatum infection attenuates antitumor immunity in esophageal squamous cell carcinoma. | Nat Commun | 2023 | https://conductscience.org/library/papers/37723150 | PubMed |
| 5 | 40,069,590 | PKN2 enhances the immunosuppressive activity of polymorphonuclear myeloid-derived suppressor cells in esophageal carcinoma by mediating fatty acid oxidation. | Mol Med | 2025 | https://conductscience.org/library/papers/40069590 | PubMed |
| 6 | 40,035,906 | The Relationship Between Gut Microbiome Bifidobacterium and Anti-tumor Immune Responses in Esophageal Squamous Cell Carcinoma. | Ann Surg Oncol | 2025 | https://conductscience.org/library/papers/40035906 | PubMed |
| 7 | 39,702,756 | EZH2 elicits CD8+ T-cell desert in esophageal squamous cell carcinoma via suppressing CXCL9 and dendritic cells. | Commun Biol | 2024 | https://conductscience.org/library/papers/39702756 | PubMed |
| 8 | 40,665,303 | Unveiling new therapeutic targets for esophageal cancer treatment through single-cell transcriptomics: pH-responsive nanobubbles enhance the efficacy of 125I radiotherapy. | J Nanobiotechnology | 2025 | https://conductscience.org/library/papers/40665303 | PubMed |
| 9 | 38,734,159 | The single cell immunogenomic landscape after neoadjuvant immunotherapy combined chemotherapy in esophageal squamous cell carcinoma. | Cancer Lett | 2024 | https://conductscience.org/library/papers/38734159 | PubMed |
| 10 | 34,019,807 | The loss of RNA N6-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8+ T cell dysfunction and tumor growth. | Cancer Cell | 2021 | https://conductscience.org/library/papers/34019807 | PubMed |
1 to 10 of 158
See all 158 referencesCited by0
The papers in our copy of PubMed whose reference list names this one, newest first.
None in this release.
Genes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42903418
GET https://conductscience.org/api/papers/v1/42903418/references?page=2